18.02
+0.245(+1.38%)
Currency In NaN
| Previous Close | 17.77 |
| Open | 17.9 |
| Day High | 18.27 |
| Day Low | 17.59 |
| 52-Week High | 29.74 |
| 52-Week Low | 12.1 |
| Volume | 16,453 |
| Average Volume | 113,183 |
| Market Cap | 659.11M |
| PE | -9.19 |
| EPS | -1.96 |
| Moving Average 50 Days | 18.16 |
| Moving Average 200 Days | 21.1 |
| Change | 0.25 |
CORRECTION -- Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders
GlobeNewswire Inc.
Jan 09, 2025 2:12 PM GMT
BOSTON and SAN DIEGO, Jan. 09, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Rapport Therapeutics, Inc. (Nasdaq: RAPP), please note the references to the AMPA-associated protein, TARP8 have been updated to th
Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders
GlobeNewswire Inc.
Jan 09, 2025 12:00 PM GMT
In the PET trial, RAP-219 achieved and exceeded target receptor occupancy, increasing support for the dosing regimen utilized in the ongoing Phase 2a trial in focal epilepsy; restricted neuroanatomical expression of TARP8 was confirmed In the MAD-2 t
Rapport Therapeutics Presents Data Demonstrating Consistent Association Between Decreases in RNS Measured Long Episodes and Meaningful Reductions in Clinical Seizures
GlobeNewswire Inc.
Dec 06, 2024 5:01 PM GMT
A 30% reduction in long episodes was shown to be associated with a 50% or greater reduction in clinical seizures in a post-hoc analysis, validating the biomarker for proof-of-concept studies Change in long episode frequency is the primary endpoint fo